SignalXSignalX

Vir Biotechnology, Inc. (VIR) 8-K Current Report: February 23, 2026

Filed: February 23, 2026
Health Care
Biological Products, (No Diagnostic Substances)
Vir Biotechnology, Inc. Overview

Vir Biotechnology, Inc. (VIR) 8-K current report filed with SEC EDGAR on February 23, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.

Reported 8-K Items
3 items

  • Item 8.01: Other Events
  • Item 1.01: Entry into a Material Definitive Agreement
  • Item 2.02: Results of Operations and Financial Condition

Vir Biotechnology, Inc. 8-K Feb 23, 2026 Event Analysis

Item 1.01 · Entry into a Material Definitive Agreement

  • • Vir Bio receives $335M upfront/near-term: $240M cash + $75M equity + $20M milestone on manufacturing transfer (expected Q2-Q3 2027)
  • • Astellas buys 7.24M shares at $10.36/share (~$75M), a 50% premium to 30-day VWAP — significant vote of confidence in VIR-5500
  • • Total deal value up to $1.705B ($335M near-term + $1.37B milestones), plus tiered double-digit royalties on ex-U.S. net sales
  • • U.S. profit/loss split 50/50; global clinical costs split 40% Vir Bio / 60% Astellas — Astellas bears majority of development burden
  • • Vir Bio opt-out option preserves flexibility: exit cost-sharing in exchange for up to $1.60B in milestones + global royalties; Sanofi entitled to a portion of proceeds per existing license

Item 2.02 · Results of Operations and Financial Condition

  • • Q4 and full-year 2025 financial results announced Feb 23, 2026
  • • Detailed figures in Exhibit 99.2 of this filing

Item 8.01 · Other Events

  • • VIR-5500 Phase 1 updated results announced Feb 23, 2026; oral presentation at ASCO GU Symposium Feb 26, 2026
  • • VIR-5500 targets prostate cancer — early-stage data readout; Phase 1 results not indicative of later-stage outcomes
  • • Filing also references an Agreement and SPA with Astellas, signaling a partnership or licensing deal in parallel

Other Vir Biotechnology, Inc. 8-K Filings

8-K Mar 4, 2026
8-K Mar 2, 2026
8-K Feb 26, 2026

Get deeper insights on Vir Biotechnology, Inc.

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.